<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00819169</url>
  </required_header>
  <id_info>
    <org_study_id>20070411</org_study_id>
    <secondary_id>QUILT-3.026</secondary_id>
    <nct_id>NCT00819169</nct_id>
  </id_info>
  <brief_title>QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors</brief_title>
  <official_title>A Phase 1b/2 Open Label, Dose Escalation Study of AMG 655 in Combination With AMG 479 in Subjects With Advanced, Refractory Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NantCell, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NantCell, Inc.</source>
  <brief_summary>
    <textblock>
      This is a multi-center, 2-part phase 1b/2 study of AMG 655 in combination with AMG 479 to be
      conducted in the United States and Spain.

      Part 1 is a dose escalation segment to identify a dose of AMG 655 in combination with AMG 479
      that is safe and tolerable.

      Part 2 will evaluate the safety and estimate the efficacy of AMG 655 at the dose selected in
      Part 1 in combination with AMG 479 for the treatment of patients with advanced NSCLC
      (non-squamous histology; squamous histology), CRC, pancreatic cancer, ovarian cancer, and
      sarcoma.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor decision - subjects rolled over to protocol 20101116
  </why_stopped>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incedence of dose limiting toxicity</measure>
    <time_frame>Length of Study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>Length of Study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to response</measure>
    <time_frame>Length of Study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Length of Study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Length of Study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate anti-AMG 655 antibody formation and anti-AMG 479 antibody formation</measure>
    <time_frame>Length of Study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the PK of AMG 655 and of AMG 479</measure>
    <time_frame>Length of Study</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">89</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Locally Advanced</condition>
  <condition>Metastatic Cancer</condition>
  <condition>Non-Small Cell Lung Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Pancreatic Cancer</condition>
  <condition>Sarcoma</condition>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Part 1 Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AMG 479 18 mg/kg IV plus AMG 655 15 mg/kg IV (day 1 of each Q3W cycle)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AMG 479 18 mg/kg IV plus AMG 655 1 mg/kg IV (day 1 of each Q3W cycle)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AMG 479 18 mg/kg IV plus AMG 655 3 mg/kg IV (day 1 of each Q3W cycle)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AMG 479 18 mg/kg IV plus AMG 655 15 mg/kg Q3W, or the MTD, as determined in Part 1 of the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AMG 479</intervention_name>
    <description>AMG 479 is an investigational, fully human, monoclonal antibody that binds with Insulin-like growth factor receptor type 1.</description>
    <arm_group_label>Part 1 Cohort 1</arm_group_label>
    <arm_group_label>Part 1 Cohort 2</arm_group_label>
    <arm_group_label>Part 1 Cohort 3</arm_group_label>
    <arm_group_label>Part 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AMG 655</intervention_name>
    <description>AMG 655 is an investigational, fully human, monoclonal antibody that binds with TNF-related apoptosis-inducing ligand, DR 5.</description>
    <arm_group_label>Part 1 Cohort 3</arm_group_label>
    <arm_group_label>Part 1 Cohort 1</arm_group_label>
    <arm_group_label>Part 1 Cohort 2</arm_group_label>
    <arm_group_label>Part 2</arm_group_label>
    <other_name>AMG 655 is also known as conatumumab.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Part 1: Histologically or cytologically confirmed, locally advanced or metastatic,
             treatment-refractory solid tumors

          -  Part 2: Histologically or cytologically confirmed, locally advanced or metastatic:
             NSCLC (squamous or non-squamous cell carcinoma; up to 2 prior treatment regimens),
             Colorectal Cancer (up to 2 prior treatment regimens), Pancreatic Cancer (up to 1 prior
             treatment regimen), Ovarian cancer (up to 2 prior treatment regimens), or Sarcoma (up
             to 2 prior treatment regimens), according to cohort availability

          -  Eastern Cooperative Group (ECOG performance status of 0 or 1

          -  Women or men ≥16 years of age

          -  Adequate hematology, renal, hepatic, coagulation and glycemic function.

        Exclusion Criteria:

          -  Presence of uncontrolled central nervous system (CNS) disease

          -  Systemic chemotherapy, hormonal therapy, immunotherapy, experimental or approved
             anticancer proteins/antibodies therapy ≤28 days before enrollment.

          -  Prior treatment with death receptor agonists (including but not limited to
             rhApo2L/TRAIL [AMG951], apomab, mapatumumab, lexatumumab, CS-1008)

          -  Prior treatment with IGF receptor antagonists (including but not limited to CP-751,
             871, MK0646, AVE1642 or IMC-A12)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <removed_countries>
    <country>Spain</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <reference>
    <citation>Tabernero J, Chawla SP, Kindler H, Reckamp K, Chiorean EG, Azad NS, Lockhart AC, Hsu CP, Baker NF, Galimi F, Beltran P, Baselga J. Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab. Target Oncol. 2015 Mar;10(1):65-76. doi: 10.1007/s11523-014-0315-z. Epub 2014 May 11.</citation>
    <PMID>24816908</PMID>
  </reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2009</study_first_submitted>
  <study_first_submitted_qc>January 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2009</study_first_posted>
  <disposition_first_submitted>July 13, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>July 13, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 3, 2015</disposition_first_posted>
  <last_update_submitted>November 2, 2016</last_update_submitted>
  <last_update_submitted_qc>November 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AMG 655</keyword>
  <keyword>AMG 479</keyword>
  <keyword>Apoptosis</keyword>
  <keyword>Monoclonal Antibody</keyword>
  <keyword>Tumor Necrosis Factor</keyword>
  <keyword>Insulin-like Growth Factor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

